Prostate Cancer Treatment Using Androgen Deprivation Therapy and Focal Prostate Ablation

This study is testing a treatment approach for intermediate-risk prostate cancer that combines androgen deprivation therapy (ADT, which lowers male hormones that fuel prostate cancer) with focal ablation (a targeted technique that destroys only the tumor area within the prostate, sparing healthy tissue). This aims to treat cancer effectively while minimizing side effects. **You may be eligible if...** - You have intermediate-risk prostate cancer confirmed by biopsy (Gleason Grade Group 2 or 3, PSA under 20 ng/mL) - Imaging shows no cancer spreading outside the prostate - You have chosen focal therapy as your treatment approach - Your cancer has not spread to distant organs or lymph nodes **You may NOT be eligible if...** - Your cancer is high-risk or has spread outside the prostate - Your PSA is above 20 ng/mL or your Gleason score is very high - You have active bladder or rectal problems affecting treatment planning - You have had prior prostate surgery or radiation Talk to your doctor to see if this trial is right for you.